|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/06/20 NovaBay Pharmaceuticals, Inc. 10-Q 6/30/20 93:10M RDG Filings/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 854K
2: EX-10.1 Material Contract HTML 78K
3: EX-10.14 Material Contract HTML 44K
4: EX-10.17 Material Contract HTML 56K
5: EX-10.31 Material Contract HTML 36K
6: EX-31.1 Certification -- §302 - SOA'02 HTML 29K
7: EX-31.2 Certification -- §302 - SOA'02 HTML 29K
8: EX-32.1 Certification -- §906 - SOA'02 HTML 27K
9: EX-32.2 Certification -- §906 - SOA'02 HTML 27K
16: R1 Document And Entity Information HTML 58K
17: R2 Condensed Consolidated Balance Sheets (Current HTML 107K
Period Unaudited)
18: R3 Condensed Consolidated Balance Sheets (Current HTML 45K
Period Unaudited) (Parentheticals)
19: R4 Condensed Consolidated Statements of Operations HTML 85K
and Comprehensive Loss (Unaudited)
20: R5 Condensed Consolidated Statements of Cash Flows HTML 143K
(Unaudited)
21: R6 Consolidated Statements of Stockholders' Equity HTML 103K
(Deficit) (Unaudited)
22: R7 Note 1 - Organization HTML 34K
23: R8 Note 2 - Summary of Significant Accounting HTML 169K
Policies
24: R9 Note 3 - Fair Value Measurements HTML 100K
25: R10 Note 4 - Prepaid Expenses and Other Current Assets HTML 46K
26: R11 Note 5 - Inventory HTML 37K
27: R12 Note 6 - Property and Equipment HTML 45K
28: R13 Note 7 - Accrued Liabilities HTML 42K
29: R14 Note 8 - Commitments and Contingencies HTML 80K
30: R15 Note 9 - Related Party Notes Payable HTML 33K
31: R16 Note 10 - Convertible Note HTML 61K
32: R17 Note 11 - Warrant Liability HTML 144K
33: R18 Note 12 - Stockholders' Equity (Deficit) HTML 76K
34: R19 Note 13 - Equity-based Compensation HTML 111K
35: R20 Note 14 - Revenue HTML 77K
36: R21 Note 15 - Employee Benefit Plan HTML 33K
37: R22 Note 16 - Related Party Transactions HTML 46K
38: R23 Note 18 - Paycheck Protection Program HTML 33K
39: R24 Note 19 - Subsequent Events HTML 34K
40: R25 Significant Accounting Policies (Policies) HTML 220K
41: R26 Note 2 - Summary of Significant Accounting HTML 117K
Policies (Tables)
42: R27 Note 3 - Fair Value Measurements (Tables) HTML 95K
43: R28 Note 4 - Prepaid Expenses and Other Current Assets HTML 46K
(Tables)
44: R29 Note 5 - Inventory (Tables) HTML 38K
45: R30 Note 6 - Property and Equipment (Tables) HTML 42K
46: R31 Note 7 - Accrued Liabilities (Tables) HTML 41K
47: R32 Note 8 - Commitments and Contingencies (Tables) HTML 62K
48: R33 Note 10 - Convertible Note (Tables) HTML 51K
49: R34 Note 11 - Warrant Liability (Tables) HTML 120K
50: R35 Note 12 - Stockholders' Equity (Deficit) (Tables) HTML 38K
51: R36 Note 13 - Equity-based Compensation (Tables) HTML 88K
52: R37 Note 14 - Revenue (Tables) HTML 60K
53: R38 Note 2 - Summary of Significant Accounting HTML 68K
Policies (Details Textual)
54: R39 Note 2 - Summary of Significant Accounting HTML 35K
Policies - Components of Cash, Cash Equivalents,
and Restricted Cash (Details)
55: R40 Note 2 - Summary of Significant Accounting HTML 39K
Policies - Disaggregation of Revenue (Details)
56: R41 Note 2 - Summary of Significant Accounting HTML 48K
Policies - Revenues and Accounts Receivable From
Major Distribution Partners and Customers
(Details)
57: R42 Note 2 - Summary of Significant Accounting HTML 47K
Policies - Calculation of Basic and Diluted EPS
(Details)
58: R43 Note 2 - Summary of Significant Accounting HTML 31K
Policies - Outstanding Stock Options and Stock
Warrants Excluded From the Diluted Net Loss Per
Share Computation (Details)
59: R44 Note 3 - Fair Value Measurements (Details Textual) HTML 31K
60: R45 Note 3 - Fair Value Measurements - Assets and HTML 48K
Liabilities Measured at Fair Value on a Recurring
Basis (Details)
61: R46 Note 3 - Fair Value Measurements - Fair Value of HTML 35K
Warrant Liability (Details)
62: R47 Note 4 - Prepaid Expenses and Other Current Assets HTML 48K
- Summary of Prepaid Expenses and Other Current
Assets (Details)
63: R48 Note 5 - Inventory - Summary of Inventory HTML 33K
(Details)
64: R49 Note 6 - Property and Equipment (Details Textual) HTML 27K
65: R50 Note 6 - Property and Equipment - Summary of HTML 42K
Property and Equipment (Details)
66: R51 Note 7 - Accrued Liabilities - Summary of Accrued HTML 43K
Liabilities (Details)
67: R52 Note 8 - Commitments and Contingencies (Details HTML 60K
Textual)
68: R53 Note 8 - Commitments and Contingencies - Lease HTML 39K
Expense (Details)
69: R54 Note 8 - Commitments and Contingencies - Schedule HTML 44K
of Future Lease Payments (Details)
70: R55 Note 9 - Related Party Notes Payable (Details HTML 53K
Textual)
71: R56 Note 10 - Convertible Note (Details Textual) HTML 92K
72: R57 Note 10 - Convertible Note - Key Assumptions Used HTML 33K
to Value the Combined Embedded Derivative
(Details)
73: R58 Note 10 - Convertible Note - Schedule of HTML 38K
Convertible Note (Details)
74: R59 Note 10 - Convertible Note - Schedule of Maturity HTML 34K
of Convertible Note (Details)
75: R60 Note 11 - Warrant Liability (Details Textual) HTML 129K
76: R61 Note 11 - Warrant Liability - The Key Assumptions HTML 58K
Used to Value the Warrants (Details)
77: R62 Note 11 - Warrant Liability - Outstanding Warrant HTML 42K
Liability (Details)
78: R63 Note 12 - Stockholders' Equity (Deficit) (Details HTML 286K
Textual)
79: R64 Note 12 - Stockholders' Equity - Outstanding HTML 40K
Warrants (Details)
80: R65 Note 13 - Equity-based Compensation (Details HTML 134K
Textual)
81: R66 Note 13 - Equity-based Compensation - Stock HTML 79K
Options Outstanding (Details)
82: R67 Note 13 - Equity-based Compensation - HTML 38K
Weighted-average Assumptions Used in Determining
the Value of Options Granted to Employees and
Directors (Details)
83: R68 Note 13 - Equity-based Compensation - Summary of HTML 33K
Stock-based Compensation Expense Included in
Results of Operations (Details)
84: R69 Note 14 - Revenue (Details Textual) HTML 97K
85: R70 Note 14 - Revenue - Changes in Assets and HTML 43K
Liabilities (Details)
86: R71 Note 14 - Revenue - Total Revenues (Details) HTML 34K
87: R72 Note 15 - Employee Benefit Plan (Details Textual) HTML 28K
88: R73 Note 16 - Related Party Transactions (Details HTML 77K
Textual)
89: R74 Note 18 - Paycheck Protection Program (Details HTML 35K
Textual)
90: R75 Note 19 - Subsequent Events (Details Textual) HTML 52K
92: XML IDEA XML File -- Filing Summary XML 170K
91: EXCEL IDEA Workbook of Financial Reports XLSX 106K
10: EX-101.INS XBRL Instance -- nby-20200630 XML 2.92M
12: EX-101.CAL XBRL Calculations -- nby-20200630_cal XML 145K
13: EX-101.DEF XBRL Definitions -- nby-20200630_def XML 1.74M
14: EX-101.LAB XBRL Labels -- nby-20200630_lab XML 1.34M
15: EX-101.PRE XBRL Presentations -- nby-20200630_pre XML 1.77M
11: EX-101.SCH XBRL Schema -- nby-20200630 XSD 288K
93: ZIP XBRL Zipped Folder -- 0001437749-20-016868-xbrl Zip 236K
Exhibit 31.2
CERTIFICATION PURSUANT TO EXCHANGE ACT
RULE 13a-14(a)/15d-14(a), AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Andrew Jones, certify that:
1. I have reviewed this Form 10-Q of NovaBay Pharmaceuticals, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: August 6, 2020
|
/s/ Andrew Jones |
|
|
|
|
|
Chief Financial Officer |
|
|
(principal financial officer) |
|
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 8/6/20 | None on these Dates | ||
| For Period end: | 6/30/20 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/04/22 NovaBay Pharmaceuticals, Inc. S-1 5:953K RDG Filings/FA 12/01/21 NovaBay Pharmaceuticals, Inc. S-1 15:1.1M RDG Filings/FA 6/11/21 NovaBay Pharmaceuticals, Inc. 8-K:8,9 6/07/21 1:26K RDG Filings/FA 3/25/21 NovaBay Pharmaceuticals, Inc. 10-K 12/31/20 101:10M RDG Filings/FA 1/15/21 NovaBay Pharmaceuticals, Inc. S-8 1/15/21 3:93K RDG Filings/FA 11/12/20 NovaBay Pharmaceuticals, Inc. 10-Q 9/30/20 89:10M RDG Filings/FA 8/21/20 NovaBay Pharmaceuticals, Inc. S-3 3:266K RDG Filings/FA |